Johnson & Johnson announced the commercial launch of its VARIPULSE Pro pulsed‑field ablation (PFA) system in Europe after receiving CE Mark approval. The platform introduces a new pulse sequence that delivers ablation five times faster at lower temperatures while achieving equivalent lesion quality, and it integrates seamlessly with the CARTO 3 System for advanced mapping.
Atrial fibrillation affects more than 50 million people worldwide, and the PFA market is expanding as clinicians seek safer, faster alternatives to radiofrequency ablation. By adding VARIPULSE Pro to its MedTech portfolio, J&J strengthens its position in the cardiovascular space, a segment that has become a key driver of growth for the company’s MedTech division.
The launch places J&J in direct competition with Boston Scientific’s Farapulse system and Medtronic’s PFA offerings. Through its Biosense Webster brand, J&J has long been a leader in electrophysiology, and VARIPULSE Pro expands that legacy into the emerging PFA arena.
Initial cases are being performed under the VARIPURE study, and additional clinical studies are planned to further evaluate safety and efficacy. The system’s integration with CARTO mapping and intracardiac echocardiography (ICE) facilitates accurate positioning and consistent lesion delivery, as noted by early adopters.
"In our early experience, VARIPULSE Pro has been exceptionally smooth and easy to use. The speed is particularly striking and contributes to more efficient procedures without compromising precision," said Tom De Potter, Head of Electrophysiology at OLV Hospital in Belgium. "The integration with CARTO mapping and intracardiac echocardiography (ICE) facilitate accurate positioning and consistent lesion delivery, contributing to a very positive procedural experience." "The introduction of VARIPULSE Pro in Europe reflects our commitment to advancing our PFA platforms through continuous innovation, enhancing procedural experience while maintaining the consistency and precision physicians expect from the VARIPULSE Platform," added Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech. "This launch demonstrates our dedication to continuously evolving PFA technologies based on real‑world learnings and our scientific expertise, supporting physicians to deliver high‑quality care and improved patient outcomes."
VARIPULSE Pro is not yet approved in the United States, but the CE Mark launch positions J&J for future regulatory submissions. The company’s recent acquisitions of Abiomed and Shockwave Medical, along with a planned separation of its orthopedics business, underscore a strategic focus on high‑growth, high‑innovation markets such as cardiovascular care. The European launch is a key milestone that could accelerate global adoption of PFA technology and expand J&J’s share of the rapidly growing atrial fibrillation treatment market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.